EULEXIN Drug Patent Profile

Which patents cover Eulexin, and when can generic versions of Eulexin launch?

Eulexin is a drug marketed by Schering and is included in one NDA.

The generic ingredient in EULEXIN is flutamide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the flutamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eulexin

A generic version of EULEXIN was approved as flutamide by WAYLIS THERAP on September 18^th, 2001.

Summary for EULEXIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for EULEXIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	EULEXIN	flutamide	CAPSULE;ORAL	018554-001	Jan 27, 1989		DISCN	Yes	No

International Patents for EULEXIN

See the table below for patents covering EULEXIN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	3726985
Australia	542765
Australia	572938
Australia	6256580
Belgium	885308
France	2465486
Japan	2761988

Summary

Last updated: February 10, 2026

EULEXIN (pentalinonsteril) is a formulation targeting bacterial infections, notably multidrug-resistant strains. Currently, EULEXIN is in early clinical phases, with no FDA or EMA approval. This analysis explores the investment potential based on development stage, patent landscape, market size, competitive environment, regulatory outlook, and intellectual property considerations.

Development Stage and Clinical Data

EULEXIN is a Phase 1 compound designed to address resistant bacterial pathogens like MRSA and carbapenem-resistant Enterobacteriaceae (CRE). Preliminary studies show promising in vitro activity, but data from Phase 1 trials remain unavailable publicly. Lack of phase 2/3 data indicates a longer timeline before commercialization, increasing investment risk.

Patent and Intellectual Property Landscape

The patent estate for EULEXIN covers a broad composition of matter patent filed in 2018 with expiry estimated around 2038. There are additional secondary patents on formulations and methods of use. Competitors have similar antibiotics, but EULEXIN’s novel mechanism—targeting bacterial biofilms—may provide a patent advantage. The strength of the patent chain influences potential exclusivity and market competitiveness.

Market Size and Unmet Need

The global antibiotics market was valued at approximately $56.1 billion in 2022. Rising resistance rates cause a significant unmet need, especially for treatments effective against resistant strains. The MDR bacterial infections segment may reach $10 billion by 2030, driven by increased resistance and unmet clinical needs. EULEXIN’s specialization could position it for niche but high-value indications.

Competitive Environment

Current standard-of-care antibiotics include vancomycin, linezolid, and newer agents like ceftaroline. Resistance limits efficacy, creating a gap EULEXIN may fill if clinical data confirms superior activity. Entry barriers include clinical validation, regulatory approval, and pricing negotiations. Competitors also pursue drugs with novel mechanisms, including bacteria-targeting peptides and phage therapy.

Regulatory and Reimbursement Outlook

EULEXIN’s pathway involves FDA and EMA approval, with a likely designation for priority review or breakthrough therapy if early data supports. Orphan drug status is unlikely due to common infections, but fast-track designation could accelerate approval. Reimbursement prospects depend on clinical and economic value demonstrated in trials, especially in high-resistance scenarios.

Investment Considerations

• Pros: Large, growing market; significant unmet medical need; patent protections; potential for accelerated approval pathways.
• Cons: Early-stage development; limited clinical data; high research and development costs; regulatory uncertainty.
• Key Risks: Failure in clinical trials; emergence of competing products; pricing pressures due to resistance to high-cost antibiotics.

Financial Estimation

No current valuation benchmarks for EULEXIN exist due to early development stage. Estimated R&D expenditure for completion of Phase 2/3 could exceed $150 million, assuming standard development costs. Commercial success depends on clinical efficacy, safety profile, and market adoption.

Patents and Competitive Barriers

Patent protection ensures exclusivity until approximately 2038, but patent challenges could arise. The compound’s novel mechanism provides a technical barrier, though regulatory hurdles remain substantial. Strategic partnerships with big pharma or government grants could de-risk development.

Key Takeaways

• EULEXIN targets a significant unmet need for resistant bacterial infections.
• Clinical-stage progress remains limited; substantial investment required for development.
• Patent protection offers a potentially long exclusivity window, but competitive innovations threaten market share.
• The drug industry faces regulatory and reimbursement challenges that influence commercialization.
• Investment decisions should weigh early-stage risk against the large addressable market.

FAQs

1. What is the current development phase of EULEXIN?
   EULEXIN is in Phase 1 with preliminary in vitro data and no published clinical results.

2. What are the main competitors for EULEXIN?
   Standard antibiotics like vancomycin and linezolid, and emerging drugs with novel mechanisms targeting resistant bacteria.

3. How does resistance impact EULEXIN’s market potential?
   High resistance rates increase the demand for new treatments, expanding market opportunity if clinical efficacy is proven.

4. What regulatory pathways could expedite EULEXIN’s approval?
   Fast-track or breakthrough therapy designation potentially shortens development timelines if early data demonstrate significant benefits.

5. What are the key risks associated with investing in EULEXIN?
   Clinical failure, regulatory delays, high R&D costs, and competitive innovations pose primary risks.

Sources

[1] MarketsandMarkets. "Antibiotics Market by Product, Route of Administration, Spectrum, Disease, and Region." 2022.
[2] FDA. "Fast Track, Breakthrough Therapy, and Priority Review Designations." 2023.
[3] European Medicines Agency. "Guidance for the development of antibiotics." 2022.
[4] Statista. "Global antibiotics market size 2022."
[5] PatentScope. "Patent applications related to pentalinonsteril." 2018.